Portal de Periódicos da CAPES

The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma

2007; Elsevier BV; Volume: 110; Issue: 3 Linguagem: Inglês

10.1182/blood-2007-01-067769

1528-0020

Sarah Park, Jeeyun Lee, Young Hyeh Ko, Arum Han, Hyun Jung Jun, Sang Chul Lee, In Gyu Hwang, Winnie Yeo, Jin Seok Ahn, Chul Won Jung, Kihyun Kım, Yong Chan Ahn, Won Ki Kang, Keunchil Park, Won Seog Kim,

Eosinophilic Disorders and Syndromes

Abstract To define prognostic impact of Epstein-Barr virus (EBV) infection in diffuse large B-cell lymphoma (DLBCL), we investigated EBV status in patients with DLBCL. In all, 380 slides from paraffin-embedded tissue were available for analysis by EBV-encoded RNA-1 (EBER) in situ hybridization, and 34 cases (9.0%) were identified as EBER-positive. EBER positivity was significantly associated with age greater than 60 years (P = .005), more advanced stage (P < .001), more than one extranodal involvement (P = .009), higher International Prognostic Index (IPI) risk group (P = .015), presence of B symptom (P = .004), and poorer outcome to initial treatment (P = .006). The EBER+ patients with DLBCL demonstrated substantially poorer overall survival (EBER+ vs EBER− 35.8 months [95% confidence interval (CI), 0-114.1 months] vs not reached, P = .026) and progression-free survival (EBER+ vs EBER− 12.8 months [95% CI, 0-31.8 months] vs 35.8 months [95% CI, 0-114.1 months], respectively (P = .018). In nongerminal center B-cell–like subtype, EBER in situ hybridization positivity retained its statistical significance at the multivariate level (P = .045). Nongerminal center B-cell–like patients with DLBCL with EBER positivity showed substantially poorer overall survival with 2.9-fold (95% CI, 1.1-8.1) risk for death. Taken together, DLBCL patients with EBER in situ hybridization+ pursued more rapidly deteriorating clinical course with poorer treatment response, survival, and progression-free survival.